Edwards Lifesciences (NYSE:EW) Given New $105.00 Price Target at JPMorgan Chase & Co.

Edwards Lifesciences (NYSE:EW) had its target price raised by JPMorgan Chase & Co. from $100.00 to $105.00 in a research report released on Friday morning,Benzinga reports. They currently have an overweight rating on the medical research company’s stock.

A number of other equities research analysts have also recently commented on EW. Canaccord Genuity Group set a $85.00 price objective on shares of Edwards Lifesciences and gave the stock a “hold” rating in a research note on Friday, April 24th. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Friday, July 17th. Royal Bank Of Canada increased their price target on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Barclays reiterated an “overweight” rating and issued a $110.00 price objective (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Finally, Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. One analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $99.55.

Edwards Lifesciences Trading Down 1.4%

Edwards Lifesciences stock opened at $82.67 on Friday. The stock has a 50-day moving average price of $87.73 and a 200 day moving average price of $83.88. The company has a market capitalization of $47.60 billion, a price-to-earnings ratio of 47.51, a price-to-earnings-growth ratio of 2.10 and a beta of 0.86. Edwards Lifesciences has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a quick ratio of 3.63, a current ratio of 4.42 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. Edwards Lifesciences’s quarterly revenue was up 13.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts anticipate that Edwards Lifesciences will post 3 EPS for the current year.

Insider Activity

In related news, VP Daniel J. Lippis sold 619 shares of the company’s stock in a transaction dated Friday, July 10th. The stock was sold at an average price of $91.70, for a total value of $56,762.30. Following the completion of the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,671,117.80. This represents a 1.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. The trade was a 3.57% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 45,577 shares of company stock valued at $3,855,527. Insiders own 0.31% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently bought and sold shares of EW. Hanson & Doremus Investment Management acquired a new stake in Edwards Lifesciences in the 1st quarter valued at about $25,000. JPL Wealth Management LLC purchased a new stake in shares of Edwards Lifesciences in the third quarter valued at about $25,000. MV Capital Management Inc. purchased a new stake in shares of Edwards Lifesciences in the fourth quarter valued at about $26,000. RMG Wealth Management LLC acquired a new stake in shares of Edwards Lifesciences in the first quarter valued at approximately $26,000. Finally, Kemnay Advisory Services Inc. acquired a new stake in shares of Edwards Lifesciences in the fourth quarter valued at approximately $27,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Edwards Lifesciences

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: Edwards Lifesciences beat Q2 estimates on both earnings and revenue, with sales rising 13.6% year over year to $1.74 billion, helped by strong demand for heart-valve products and growing adoption of mitral and tricuspid therapies.
• Positive Sentiment: The company raised the low end of its full-year revenue outlook to $6.6 billion-$6.9 billion and also lifted its TAVR growth guidance, signaling management confidence in continued momentum.
• Positive Sentiment: Analysts turned more constructive after the report: JPMorgan raised its price target to $105 and kept an overweight rating, while Leerink upgraded the stock to outperform with a $101 target.
• Positive Sentiment: Commentary from Wall Street framed the quarter as evidence that Edwards remains a top medtech growth story, with its core TAVR franchise and newer structural heart therapies driving the upside.
• Neutral Sentiment: The company’s updated Q3 and full-year EPS guidance was broadly in line with expectations, suggesting the current move is being driven more by sales strength and sentiment than by a major earnings surprise.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.